In the 2023, how to better empower the research and development of new drugs? How to better meet the R&D needs of global clients? How to organize resources and build an ecosystem... This is a heavy "examination paper" thrown to Medicilon by the times.
As an enabler of the pharmaceutical industry, Medicilon adheres to its original mission, works hard and moves forward resolutely, writing Medicilon's "answer"for 2023!
1
Focusing on the integrated strategy of preclinical research, Medicilon continued to deepen the integrated development, extended the advantages of integration from chemical drugs to the field of biological drugs, and further complement the capabilities of drug discovery and pharmaceutical research capabilities of biological drugs.
By introducing advanced equipment investment and a team of senior talents, Medicilon has improved its one-stop preclinical R&D service platform for ADC drugs and small nucleic acid drugs, and seized development opportunities in the field of pharmaceutical R&D.
2
Facing the challenges and opportunities of the new round of industrial revolution, Medicilon has been accumulating scientific and technological innovation strength through independent innovation, external collaboration and technology introduction, helping the scientific and technological innovation to make profit.
In 2023, Medicilon has followed the hot trends in R&D, strengthened and improved the construction of a preclinical safety evaluation platform for botanical drug. Medicilon is actively expanding into new formulation R&D areas such as nanobody formulations; established and improved a BSL-2 laboratory for the research of cell and oncolytic virus drugs, and strengthened the R&D technology platforms such as computer-aided drug design (CADD) and artificial intelligence (AI) technology… Medicilon is determined to move forward on the road of innovation.
In addition, Medicilon launched Pharmalego, an e-commerce platform for intermediates, to support the new drug development in the whole process, from high-end intermediates to customization.
3
According to incomplete statistics, in 2023, a total of about 90 new drugs and generic drug projects have been approved for clinical trials all over the world, which is a strong interpretation of " Medicilon speed and quality", helping drugs to be rapidly pushed into clinical practice and seizing opportunity to overtake the market.It is worth mentioning that Medicilon has accumulated rich R&D experience in the fields of ADC, small nucleic acids, PROTAC, and GLP-1. Medicilon have served more than 50 ADC clients ,with more than 30 projects under research,; it has served more than 40 small nucleic acid clients and has more than 20 projects under research,; it has served more than 30 PROTAC-related clients and nearly 20 projects are under research, and have helped 8 GLP-1 related drugs obtain clinical approval.
4
In August, Medicilon successfully completed the refinancing project of issuing A-shares to specific targets and received RMB 985 million net raised funds. Medicilon is currently promoting the construction of two investment projects for this private placement: the main structure of the laboratory expansion project in Nanhui Park has been fully capped, and the construction of Baoshan Park has officially started. After completion, it will further enhance the scale and level of new drug R&D services, and be able to proactively and deeply empower more global innovative drug research and development.
In order to respond to R&D needs in a timely manner, Medicilon's laboratory facilities have obtained GLP certification qualifications from the National Medical Products Administration. The scope of GLP services has increased from 8 to 9, and the GLP laboratory area has increased from 11,000 square meters to 29,000 square meters. The ABSL-2 laboratory has obtained the "Shanghai Pudong New Area Animal Pathogenic Microorganism Laboratory Registration Certificate" issued by the Shanghai Pudong New Area Agriculture and Rural Affairs Committee, becoming a one-stop pharmaceutical preclinical R&D service platform with both ABSL-2 and BSL-2 laboratories!
5
As one of the earliest Chinese CROs to enter the U.S. market, Medicilon's R&D base in Boston, U.S.A., has been gradually put into operation, and will be used as a base to take a key step forward in its globalization strategy.
At the same time, Medicilon further expanded domestic and international markets. In China, Medicilon participated in 39 conferences, including the 2023 Enmore Bio Conference and the 9th China Bio-Pharm Partnering Forum. For overseas, based on the existing overseas BD teams in the United States, Europe, Japan and South Korea, we continued to strengthen the construction of the BD team and participated in more than 30 conferences and exhibitions, including Society of Toxicology (SOT), American Association for Cancer Research (AACR) and EUROTOX 2023. In addition, we increased the frequency of expansion of the scientific research team, widely covered more potential clients worldwide.
6
Based on the existing one-stop pharmaceutical preclinical R&D service platform, Medicilon has built a new drug empowerment ecosystem and established an academician innovative drug maturation center - a new drug ecological assistance platform (including a new drug investment and financing assistance platform and a new drug R&D trading platform). Relying on Medicilon's one-stop preclinical R&D service platform, we have built an innovative R&D service platform in cutting-edge fields such as nucleic acid drugs, cellular immunity, and mRNA vaccines and have provided new drug R&D services to more than 70 clients，of which 6 have already settled in.
At the same time, Medicilon has reached strategic collaboration with North America 100 Angel Investment LLC, Fosun Health Capital, SciMatchmaker, and EyeCure. Deepen school-enterprise cooperation with China Pharmaceutical University and Putian University to build a new drug empowerment ecosystem, promote collaborative innovation among industry, academia, research and finance, and promote the integration and orderly development of the pharmaceutical industry. In addition, Medicilon donated RMB 5 million RMB to the Fudan University Education Foundation to support the development of education.
7
This year, Medicilon hosted 7online broadcast courses about PROTAC, ADC, and nucleic acids, focusing on solving key and difficult problems through the analysis of classic cases, which imparted experience and advice to pharmaceutical colleagues and answers their questions.
Meanwhile, Medicilon co-organized/sponsored 30 forums in China, including the 2023 Zhangjiang AI Intelligent Drug Forum, the "Focus on Ophthalmic Drugs, Facing R&D Challenges" seminar, and the Medicilon × GF Securities M-GF Series Symposium.
Medicilon has also sponsored 3 overseas forums including the 2023 SAPA, 25th SAPA-NE, and 22nd San Diego Biopharma Conference to share technical knowledge, to discuss opportunities and challenges, to promote industry exchanges, and to deepen multi-party collaboration. This empowered the progress and development of Chinesepharmaceutical industry.
8
Every trust starts with value, and every honor builds reputation. This year, honors, banners, and letters of thanks from the government, capital funding, industry and clients have painted the corporate image of Medicilon’s professional services. This is not only the market’s recognition of Medicilon’s technical strength, but also an incentive and spur for future empowerment.
This year, Medicilon was selected into the first batch of innovative enterprise headquarters in Shanghai and won the "2022 Science and Technology Innovation Contribution Award" in Baoshan District , which is an authoritative award from the government.
This year, Medicilon was selected into the "Science and Technology Innovation 100 Index" has raised funds of RMB 1 billion. Medicilon also won the 2023 "Golden Bull Science and Technology Innovation Award", the 2023 Science and Technology Innovation Board Hard Technology Leading Enterprise, the 2023 Growth Potential "Star" Company, the 2022 Listed Company Enterprise Number "Investment Elite Award", the 3rd Drug Innovation World Award "Top Ten of the Year" "Drug Innovation Service Agency" and other honorary titles have been recognized by the capital market.
This year, Medicilon won the 2023 "Influential Preclinical CRO Company", the Top 20 Chinese Pharmaceutical CRO Companies in 2023, the "Top 50 Chinese Pharmaceutical R&D Companies" in 2022-2023, the 2022 Chinese CXO Company Top 20 Ranking, and "Top 10 Most Influential CRO Enterprises" in the 2023 China pharmaceutical Industry Value List.
During the year,, Medicilon wined the praise from clients., was awarded the "Best Partner Award" by Leading Tac Pharma and the "Outstanding Contribution Team Award" by Jingxin Pharmaceuticals.
Standing at the end of 2023 and the beginning of 2024, changes are growing, and examination are constantly being renovated. After twenty years of success, Medicilon will continue to take the road of innovation and empowerment, continue to deliver excellent results, and move forward to empowering drug R&D in an all-round way!
Founded in 2004, Medicilon (Stock Code: 688202.SH) has grown into one of the professional drug discovery contract research organizations (CRO) in China. Over the years, Medicilon keeps improving their services in biotechnology and pharmaceutical research. Their services now span across medicinal chemistry, process chemistry, in vitro and in vivo DMPK, preclinical development and bioanalytical support. By the end of 2023, Medicilon has provided new drug R&D services to more than 2,000 clients around the world, and participated in the R&D of 385 new drug projects that have been approved for clinical trials. Medicilon will continue to contribute to human health by focusing on new drug from a global perspective!
Relevant
news
marketing@medicilon.com
